台股 » 個股 » 逸達 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

逸達

(6576)
  • 股價
    79.9
  • 漲跌
    ▼1.7
  • 漲幅
    -2.08%
  • 成交量
    220
  • 產業
    上櫃 生技醫療類股
  • 117人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
逸達 (6576)籌碼相關-第一金-高雄 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

第一金-高雄 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2026/07/16881.0100.0081.6081854.30%
2026/07/08183.9000.0084.1011880.53%
2026/06/12479.1000.0079.1041592.51%
2026/06/111279.3000.0079.00121607.49%
2026/06/10579.7000.0080.0051593.14%
2026/05/2900.001077.0977.00-10159-6.26%
2026/05/2800.00377.6077.60-3160-1.87%
2026/05/2700.00878.1478.10-8162-4.91%
2026/05/15178.10179.0079.0001670.00%
2026/05/061080.251280.5879.50-2176-1.13%
2026/05/04178.60179.5079.5001800.00%
2026/04/23379.9300.0081.0031871.60%
2026/04/22579.5000.0082.2051852.70%
2026/04/1600.001077.0077.00-10168-5.94%
2026/04/1500.00177.0077.00-1168-0.59%
2026/04/1400.00477.0077.00-4167-2.39%
2026/04/02076.6000.0077.0001710.00%
2026/03/10081.0000.0080.7001730.00%
2026/03/0900.00380.4080.40-3173-1.73%
2026/03/0400.00380.2080.20-3177-1.69%
2026/03/0300.00482.5082.50-4176-2.26%
2026/03/0200.00583.0283.50-5177-2.82%
2026/02/2300.00283.8083.90-2179-1.12%
2026/02/0600.00185.6087.00-1230-0.43%
2026/02/05186.4000.0086.6012280.44%
2026/02/0300.00184.0084.00-1223-0.45%
2026/02/0200.00183.4083.70-1221-0.45%
2026/01/30181.8000.0082.8012170.46%
2026/01/28182.0000.0082.4012160.46%
2026/01/27382.30383.1382.8002150.00%
2026/01/2600.00181.0082.20-1212-0.47%
2026/01/2300.00180.4080.30-1209-0.48%
2026/01/21179.3000.0079.2012090.48%
2026/01/1600.00180.9080.90-1205-0.49%
2026/01/14179.3000.0080.0012030.49%
2026/01/09179.70281.0080.80-1212-0.47%
2026/01/05179.1000.0080.4012140.47%
2025/12/0500.00479.3579.70-4247-1.62%
2025/10/2700.00078.4078.5002800.00%
2025/08/2900.00575.7877.50-5184-2.71%
2025/08/2600.001081.0581.40-10155-6.41%
2025/08/0500.00278.4579.70-2122-1.64%
2025/08/04276.5000.0080.2021201.67%
2025/07/2500.00373.5073.50-3105-2.83%
2025/07/2200.00872.6872.10-8113-7.07%
逸達SIF技術平台跨足中樞神經系統領域 兩項候選藥物明年進入人體臨床試驗Anue鉅亨-2026/05/22
逸達 相關文章
逸達 相關影音